Anti Inflammatory Lipid Mediators in Asthma: A Double Blind Placebo Control Cross Over, Proof of Concept Study of CXA-10 to Reduce Bronchial Hyperresponsiveness in Obese Asthmatics
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs CXA 10 (Primary)
- Indications Asthma
- Focus Proof of concept; Therapeutic Use
- Acronyms ALMA
- 03 Oct 2019 Planned primary completion date changed from 1 Aug 2020 to 1 Aug 2021.
- 03 Oct 2019 Status changed from not yet recruiting to recruiting.
- 10 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Mar 2019.